Tepotinib Medication Guide: A New Choice for the Treatment of MET Mutated Non-Small Cell Lung Cancer

Drug introduction: Tepotinib (Tepotinib), also known as Tepmetko, is a drug that targets the mesenchymal epidermal transforming factor receptor (< A good drug for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with skip mutations in exon 14 of span>MET. Such mutations have been confirmed through sophisticated genetic testing, and clinical practice has shown that patients respond well to tepotinib.

1. Drug effects and mechanisms

Tepotinib, as an oral small molecule tyrosine kinase inhibitor (TKI), specifically targets the MET receptor. When the MET gene is abnormally activated, such as skip mutations in exon 14, it will promote the proliferation, survival and migration of tumor cells. Tepotinib can precisely inhibit the activity of MET tyrosine kinase, thereby blocking its downstream signaling pathways and effectively curbing the growth and spread of tumor cells.

2. Instructions for drug use

The recommended dosage of Tepotinib is 450 mg per day, which can be taken once orally. Patients can choose to take it before or after a meal, but they should make sure to take it at a fixed time every day to ensure stable blood concentration. If you occasionally forget to take a dose, you should take it as soon as possible. However, if the next dose is very close (for example, less than 8 hours), you can skip this time and continue taking the medicine as originally planned.

3. Possible side effects

Common side effects include edema, nausea, vomiting, diarrhea, fatigue, and rash. In addition, there are some more serious side effects that require vigilance, such as abnormal liver function (shown as elevated transaminases and bilirubin), interstitial lung disease (symptoms include dyspnea, cough, etc.), cardiovascular events (such as hypertension, heart failure), and gastrointestinal bleeding (melena and hematemesis may occur). Other side effects of concern include loss of appetite, stomatitis, and constipation.

4. Important warnings and precautions

1.Before starting treatment and during treatment, patients should undergo liver function tests regularly. Once abnormalities are found, the drug dose should be adjusted immediately or treatment should be suspended.

2.If symptoms of interstitial lung disease such as dyspnea and cough occur, timely medical evaluation is required.

3.Patients should monitor blood pressure and cardiac function, especially those with a history of cardiovascular disease.

4.For patients with renal insufficiency, in addition to routine renal function monitoring, drug dosage may also need to be adjusted according to specific conditions.

5. Taboo groups

Patients who are allergic to any component of tepotinib, as well as pregnant and breastfeeding women, should refrain from use as this drug may pose a potential risk to the fetus and infant.

6. Interactions between drugs

Since tepotinib is mainly metabolized by CYP3A4, concomitant use with strong CYP3A4 inhibitors (such as ketoconazole) or inducers (such as rifampicin) should be avoided to avoid affecting the metabolism of the drug. At the same time, as tepotinib is a substrate of P-gp, caution should be used when combined with P-gp inhibitors (such as amiodarone), as this may increase the concentration of tepotinib in plasma.

7. Medication recommendations for special patient groups

1.Children: There is currently insufficient data to support the safe use of tepotinib in children.

2.Geriatric: Although dose adjustment is usually not necessary, greater attention should be paid to monitoring for adverse reactions.

3.Patients with hepatic or renal insufficiency: Mild to moderate insufficiency generally does not require dose adjustment, but close monitoring is required; for patients with severe insufficiency, it should be used with caution.

Tepotinib, as an innovative targeted therapy, provides a new treatment strategy for patients with metastatic non-small cell lung cancer with METexon14 skipping mutations. However, in order to ensure the safety and effectiveness of treatment, patients should strictly follow medical instructions and conduct necessary health monitoring regularly.